Rho’s free webinar, “Are you really ready for your end of phase 2 meeting?”, will take place on Wednesday, December 4, from 1-2 p.m. EST and will benefit companies nearing completion of their phase 2 studies or those planning phase 3 programs.
WHAT: The end-of-phase 2 (EOP2) meeting with the FDA is a critical milestone in your drug development program and likely the most important interaction you will have with the Agency. Getting the most from this meeting can help successfully launch your phase 3 program and help you begin preparing for your marketing application (NDA/BLA) submission.
Rho’s free webinar, “Are you really ready for your end of phase 2 meeting?”, will take place on Wednesday, December 4, from 1-2 p.m. EST and will benefit companies nearing completion of their phase 2 studies or those planning phase 3 programs. Topics to be covered include:
- Setting goals for your EOP2 meeting
- What does it mean to be phase 3 ready?
- Developing the right questions to obtain clarity from the FDA
- Timing considerations
- Common themes in FDA feedback
WHO: David Shoemaker, Ph.D., senior vice president, R&D, Rho
Kevin Barber, Ph.D., RAC, PMP, vice president, regulatory strategy and submissions, Rho
WHEN: Wednesday, December 4, 2019, 1-2 p.m. EST
WHERE: Register to attend this free webinar at this link.
DETAILS: For media inquiries, please contact Kelly Maicon at Largemouth Communications, 919-459-6450, kmaicon@largemouthpr.com.
ABOUT: Rho, a privately-held, contract research organization (CRO) located in Research Triangle Park, NC, provides a full range of clinical research services across the entire drug development process. For 35 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Facebook, LinkedIn and Twitter.
